Pharmaceutics (Jun 2023)

Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches

  • Hicham Wahnou,
  • Ibtissam Youlyouz-Marfak,
  • Bertrand Liagre,
  • Vincent Sol,
  • Mounia Oudghiri,
  • Raphaël Emmanuel Duval,
  • Youness Limami

DOI
https://doi.org/10.3390/pharmaceutics15061767
Journal volume & issue
Vol. 15, no. 6
p. 1767

Abstract

Read online

Prostate cancer is a major health concern worldwide, and current treatments, such as surgery, radiation therapy, and chemotherapy, are associated with significant side effects and limitations. Photodynamic therapy (PDT) is a promising alternative that has the potential to provide a minimally invasive and highly targeted approach to treating prostate cancer. PDT involves the use of photosensitizers (PSs) that are activated by light to produce reactive oxygen species (ROS), which can induce tumor cell death. There are two main types of PSs: synthetic and natural. Synthetic PSs are classified into four generations based on their structural and photophysical properties, while natural PSs are derived from plant and bacterial sources. Combining PDT with other therapies, such as photothermal therapy (PTT), photoimmunotherapy (PIT), and chemotherapy (CT), is also being explored as a way to improve its efficacy. This review provides an overview of conventional treatments for prostate cancer, the underlying principles of PDT, and the different types of PSs used in PDT as well as ongoing clinical studies. It also discusses the various forms of combination therapy being explored in the context of PDT for prostate cancer, as well as the challenges and opportunities associated with this approach. Overall, PDT has the potential to provide a more effective and less invasive treatment option for prostate cancer, and ongoing research is aimed at improving its selectivity and efficacy in clinical settings.

Keywords